Table 2 The mediation effects of body mass index on glucose-lowering drug targets and risks of gastrointestinal cancer

ABCC8 + KCNJ11

Anal Carcinoma

1.102

[0.757, 1.604]

1.185%

0.612

Hepatocellular Carcinoma

0.908

[0.649, 1.269]

2.067%

0.571

Intrahepatic Cholangiocarcinoma

0.759

[0.257, 2.244]

4.527%

0.618

Pancreatic Cancer

0.938

[0.884, 0.995]

3.001%

0.033

DPP4

Anal Carcinoma

1.012

[0.694, 1.475]

0.097%

0.950

Intrahepatic Cholangiocarcinoma

0.967

[0.327, 2.859]

0.377%

0.951

GLP1R

Anal Carcinoma

0.980

[0.672, 1.429]

0.218%

0.916

Cardia Cancer

1.039

[0.609, 1.774]

0.669%

0.888

GPD2

Rectum Cancer

0.997

[0.958,1.038]

0.055%

0.880

PPARG

Anal Carcinoma

1.006

[0.690, 1.466]

0.156%

0.976

Gastric Cancer

1.003

[0.845, 1.191]

0.113%

0.972

Hepatocellular Carcinoma

0.994

[0.710, 1.393]

0.140%

0.973

Intrahepatic Cholangiocarcinoma

0.984

[0.333, 2.908]

0.756%

0.976

Pancreatic Cancer

0.996

[0.930, 1.067]

0.311%

0.913

PRKAB1

Intrahepatic Cholangiocarcinoma

1.381

[0.466, 4.091]

5.125%

0.560

SLC5A2

Cardia Cancer

1.222

[0.713, 2.092]

5.313%

0.466

Hepatocellular Carcinoma

1.111

[0.789, 1.564]

2.277%

0.548

Pancreatic Cancer

1.072

[0.978, 1.174]

3.663%

0.136